Abstract is: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour. Common side effects include headache, intestinal upset, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied while use during breastfeeding is not recommended. Famotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2020, it was the 66th most commonly prescribed medication in the United States, with more than 10 million prescriptions.
| P3780 | active ingredient in | Pepcid | Q47521980 |
| Calmicid | Q48829209 | ||
| P4250 | defined daily dose | 40 | |
| P1552 | has characteristic | bitterness | Q1517187 |
| P366 | has use | medication | Q12140 |
| P8026 | LiverTox likelihood score | LiverTox toxicity likelihood category C | Q83284310 |
| P2067 | mass | 337.044936 | |
| P2175 | medical condition treated | urticaria | Q187440 |
| duodenal ulcer | Q355170 | ||
| heartburn | Q537297 | ||
| Zollinger–Ellison syndrome | Q218712 | ||
| gastroesophageal reflux disease | Q223591 | ||
| indigestion | Q653971 | ||
| peptic esophagitis | Q2184368 | ||
| gastric ulcer | Q4003020 | ||
| peripheral vascular disease | Q26695607 | ||
| P3489 | pregnancy category | Australian pregnancy category B1 | Q3679232 |
| US pregnancy category B | Q28123616 | ||
| P769 | significant drug interaction | Ketoconazole | Q407883 |
| posaconazole | Q906453 | ||
| pazopanib | Q7157043 | ||
| dasatinib monohydrate | Q27139135 | ||
| P2868 | subject has role | H2 antagonists | Q409444 |
| anti-ulcer drug | Q41602594 | ||
| P2275 | World Health Organisation international non-proprietary name | famotidine |